ArticleNature communications2024
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
164 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Trial
- Broad cross-T cell immunity between emerging SARS-CoV-2 serotypes waved by spike-signature mutations.Emerging microbes & infections · 2026Article
- Long-Term Wastewater Genomic Surveillance Reveals SARS-CoV-2 Variant Dynamics in Italy from 2021 to 2025.Food and environmental virology · 2026Article
- Article
- A dimeric mRNA vaccine based on key-mutant and KP.3 RBDs induces broad-spectrum immunity and protects mice against JN.1 and XDV challenges.Molecular biomedicine · 2026Article
- Durability and Breadth of Neutralizing Antibodies Against SARS-CoV-2 Variants Following XBB.1.5 Vaccination in a Multiply Exposed Cohort.Open forum infectious diseases · 2026Article
- Temperature-dependent replication and sensitivity to innate immunity of human coronavirus HKU1.Nature communications · 2026Article
- Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates.EBioMedicine · 2026Article
- Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants.Journal of virology · 2026Article
- Article
- SARS-CoV-2 Omicron BA.2.86 and JN.1 expand tropism in human proximal intestinal epithelium.Nature communications · 2026Article
- Characterization of recombinant genomes of the omicron variant of SARS-CoV-2 between 2022 and 2023 in the department of Antioquia, ColombiaBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Induction of Humoral and Cellular Immunity After SARS-CoV-2 JN.1 Vaccination in Individuals With and Without Prior Infection.European journal of immunology · 2026Article
- SARS-CoV-2 Evolution and Its Implications for RT-PCR Diagnostic Performance.Journal of medical virology · 2026Article
- Monitoring viral evolution and epidemiological characteristics of SARS-CoV-2 during 2022-2023 using Integrated Genomic Surveillance.Communications medicine · 2026Article
- Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape.PLoS pathogens · 2026Article
- SARS-CoV-2 nucleocapsid protein variants have differential RNA chaperone activity.The FEBS journal · 2026Article
- Article
- Intra-Omicron Reinfection with JN.1.16 and NB.1.8.1 in a Preterm Infant: First NB.1.8.1 Detection in Tunisia-A Case Report.Microorganisms · 2026Article
104 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
25 authors.
Funding
Abstract
The unceasing circulation of SARS-CoV-2 leads to the continuous emergence of novel viral sublineages. Here, we isolate and characterize XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 and JN.1 variants, representing >80% of circulating variants in January 2024. The XBB subvariants carry few but recurrent mutations in the spike, whereas BA.2.86.1 and JN.1 harbor >30 additional changes. These variants replicate in IGROV-1 but no longer in Vero E6 and are not markedly fusogenic. They potently infect nasal epithelial cells, with EG.5.1.3 exhibiting the highest fitness. Antivirals remain active. Neutralizing antibody (NAb) responses from vaccinees and BA.1/BA.2-infected individuals are markedly lower compared to BA.1, without major differences between variants. An XBB breakthrough infection enhances NAb responses against both XBB and BA.2.86 variants. JN.1 displays lower affinity to ACE2 and higher immune evasion properties compared to BA.2.86.1. Thus, while distinct, the evolutionary trajectory of these variants combines increased fitness and antibody evasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.